AUTHORS
Roisin Puentes, PharmD, PhD, Madhuri Paul, PhD2, Christodoulos Pipinikas, PhD3, John M. Furgason, PhD4, Timothy J. Stuhlmiller, PhD5, Amber Chevalier, N/A6, Derek Lyle, MD7
AFFILIATIONS
1 Neogenomics, Fort Myers, Florida, United States
2 Neogenomics, Fort Myers, Florida, United States
3 Neogenomics, Fort Myers, California, United States
4 Neogenomics, Fort Myers, Florida, United States
5 XCures, Oakland, California, United States
6 Neogenomics, Fort Myers, Florida, United States
7 Neogenomics, Fort Myers, Florida, United States
ABSTRACT
Background
Comprehensive Genomic Profiling (CGP) has become an essential component of the evaluation and management of myeloid malignancies by improving diagnostic classification, prognostic risk stratification, identification of therapeutic targets, and selection of biomarker-directed therapies. Despite established clinical utility and incorporation into clinical practice, reimbursement for CGP remains inconsistent and frequently denied.
Aims
To characterize the clinical and molecular landscape of unreimbursed CGP in patients with myeloid malignancies and evaluate the impact of genomic findings on subsequent treatment decisions and therapy initiation.
Methods
We performed a retrospective analysis of patients undergoing CGP at NeoGenomics Laboratories between January 1, 2025, and June 30, 2026, using the . Unreimbursed claims were identified across commercial, managed care, government and other payers. The landscape of molecular findings, disease indications, and clinical characteristics associated with unreimbursed testing was evaluated. Clinical findings on a subset of patients harboring pathogenic/likely pathogenic (P/LP) alterations were obtained through the Healthcare Information Exchange (HIE) to assess treatment initiation, biomarker-directed therapy, and time from CGP results to treatment.
Results
Among 46,487 myeloid patients tested with CGP, 13,721 (29.5%) had unreimbursed testing. Of these, 11,820 (86.1%) harbored clinically significant P/LP genomic alterations.
The most common myeloid malignancy indications among the unreimbursed patients included myelodysplastic syndromes (n=4,454), acute myeloid leukemia (n=878), myeloproliferative neoplasms (n=789), chronic myelomonocytic leukemia (n=102), and chronic myeloid leukemia (n=101). Reimbursement denials occurred across a spectrum of clinical presentations, including anemia (D64.9; n=4,574), thrombocytopenia (D69.6; n=2,750), aplastic anemia/cytopenias (D61.818; n=2,180), myelodysplastic syndrome (D46.9; n=1,306), and white blood cell abnormalities (D72.819/D72.829; n=3,418), indicating specific ICD10 codes where myeloid patients were frequently affected by unreimbursed testing.
The most prevalent pathogenic alterations involved TET2 (n=1,654), DNMT3A (n=1,218), ASXL1 (n=1,208), SRSF2 (n=844), and TP53 (n=673). Detected genomic alteration classes included single nucleotide variants (n=11,872), deletions (n=2,607), insertions (n=2,013), substitutions (n=529), copy number variants (n=473), and gene fusions (n=364).
Medical records retrieved from the HIE were available for 1,734 patients with P/LP alterations. Among these patients, 950 received systemic therapy, and 321 received biomarker-directed targeted therapy. The median time from test result availability to treatment initiation was 8 days (IQR, 4–21). Targeted therapy was initiated within 30 days of testing in 94 patients, within 31–60 days in 13 patients, and within 61–90 days in 6 patients. CGP identified actionable genomic alterations that directly informed treatment selection including BCR::ABL1 and PML::RARA gene fusions, and variants in FLT3, IDH1, IDH2, JAK1/JAK2, KIT, BTK, CRBN, and SYK. Patients received tyrosine kinase inhibitors, FLT3 inhibitors, IDH1/2 inhibitors, JAK inhibitors, BTK inhibitors, anti-CD20 therapies, cereblon-targeting agents, and differentiation therapy for PML::RARA-positive acute promyelocytic leukemia, demonstrating translation of genomic findings from the CGP panels into real-world treatment decisions.
Conclusions
Nearly one-third of comprehensive genomic profiling in patients with myeloid malignancies was unreimbursed despite an 86.1% rate of clinically significant genomic findings. CGP identified actionable alterations that rapidly informed personalized treatment decisions, with therapy initiated a median of 8 days following testing. These real-world data highlight the disconnect between the clinical utility of genomic results and the lack of reimbursement for testing in myeloid patients, creating a burden across the healthcare ecosystem for diagnostic laboratories, clinicians, and patients. Improved recognition and reimbursement of CGP may support sustainable access to precision diagnostics and biomarker-directed therapies across myeloid malignancies.
DISCLOSURES
Roisin Puentes, PharmD, PhD: NeoGenomics Laboratories, Inc. - Stock (publicly traded); NeoGenomics Laboratories, Inc. - Current Employment